Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.69 |
| ▸ | DRD4 | P21917 | 4/20 | 0.69 |
| ▸ | DRD3 | P35462 | 4/20 | 0.69 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8844705 | 0.86 | SIGMAR1 (0.75) | DRD2DRD4DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9085253 | 0.85 | SIGMAR1 (0.74) | DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL8844793 | 0.85 | SIGMAR1 (0.65) | DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL9364067 | 0.84 | SIGMAR1 (0.64) | DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL8844753 | 0.83 | SIGMAR1 (0.73) | DRD2DRD4DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL9083278 | 0.82 | SIGMAR1 (0.72) | DRD2DRD4DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8844630 | 0.78 | SIGMAR1 (0.59) | DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL9364027 | 0.77 | SIGMAR1 (0.77) | DRD2DRD4DRD3SIGMAR1 | |
| Hydrochloric Acid SCHEMBL8845366 | 0.77 | SIGMAR1 (0.72) | DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL30279503 | 0.75 | SIGMAR1 (1.00) | DRD2DRD4DRD3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0512525-B1 | Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist | OTSUKA PHARMA CO LTD (JP) | 1994-11-30 | — | — | EP | claimed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | BRAINCELLS, INC. (US) | 2010-01-14 | — | — | US | disclosed |
| US-5656633-A | Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5556857-A | SIGMA RECEPTOR AGONIST | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| EP-0512525-B1 | Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist | OTSUKA PHARMA CO LTD (JP) | 1994-11-30 | — | — | EP | disclosed |
| EP-0512525-A1 | Carbostyril derivatives and pharmaceutical compositions containing the same for use as a disturbance-of-consciousness improving agent, central nervous system stimulant or sigma receptor agonist | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009983-A1 | 5 HT RECEPTOR MEDIATED NEUROGENESIS | HTR6, GAP43, HTR5A | DRD2 242/4885DRD4 301/4885DRD3 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.